However, safety assessments of oral semaglutide in the SOUL trial ( 5 Conclusion Semaglutide significantly reduces cardiovascular risk in patients with T2DM, primarily by improving MACE, nonfatal myocardial infarction, and revascularization outcomes, while modestly lowering HF hospitalization risk
This article analyzes the complete clinical dataset: Phase 2 results from 2023, TRIUMPH-4 Phase 3 data from December 2025, TRIUMPH-1 Phase 3 data from May 2026, TRANSCEND-T2D-1 data from June 2026, sleep apnea substudy results, safety profiles, and what the remaining TRIUMPH trials might reveal
With active development now across Europe, Canada, and the U.S., we are advancing one of the most progressed DMOAD programs toward patients who urgently need disease-modifying options
If you miss a dose, the PIL advises: if fewer than five days have passed since the missed dose, administer it as soon as you remember
If the box is discarded, wrap the vial in aluminum foil or place it in an opaque container